Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in
Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study
of the Spanish Group for Research on Sarcomas (GEIS) by López-Pousa, A. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2006, Article ID 26986, Pages 1–8
DOI 10.1155/SRCM/2006/26986
ClinicalStudy
Phase II Trial of Doxorubicin Plus Escalated High-Dose
Ifosfamide in Patients With Advanced Soft Tissue
Sarcomas of the Adult: A Study of the Spanish
Group for Research on Sarcomas (GEIS)
A. L´ opez-Pousa,1 J. Mart´ ın,2 J. Montalar,3 R. de las Pe˜ nas,4 J. Garc´ ıa del Muro,5 J. Cruz,6 J. Maurel,7
P. Escudero, 8 A. Casado,9 J. M. Buesa,10 and the Spanish Group for Research on Sarcomas (GEIS)
1Medical Oncology Department, Hospital Sant Pau, 08025 Barcelona, Spain
2Medical Oncology Department, Hospital Son Dureta, 07014 Palma de Mallorca, Spain
3Medical Oncology Department, Hospital Cl´ ınico La Fe, 46009 Valencia, Spain
4Medical Oncology Department, Hospital Provincial, 12002 Castell´ on, Spain
5Medical Oncology Department, Instituto Catal´ an de Oncolog´ ıa, 08907 Barcelona, Spain
6Medical Oncology Department, Hospital Universitario de Canarias, 38320 Tenerife, Spain
7Medical Oncology Department, Hospital Cl´ ınic, 08036 Barcelona, Spain
8Medical Oncology Department, Hospital Cl´ ınico, 50009 Zaragoza, Spain
9Medical Oncology Department, Hospital Cl´ ınico San Carlos, 28040 Madrid, Spain
10Medical Oncology Department, Hospital Central de Asturias, Instituto Universitario de Oncolog´ ıa del Principado
de Asturias (IUOPA), 33006 Oviedo, Spain
Received 27 December 2005; Revised 22 May 2006; Accepted 6 June 2006
Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50
mg/m2 every 4 weeks in patients with soft tissue sarcomas. Methods. DXR was given IV bolus and IFOS by continuous infusion at
2g / m 2/day. Initial IFOS dose (12 g/m2) was adjusted to 10, 13, or 14 g/m2 according to toxicity. Results. Seventy patients received
277 cycles (median 3 cycles, range 1–10), 34% with IFOS dose increased, 30% decreased, and 48% delivered at 12 g/m2. Toxicity
grade 4 occurred on granulocytes (67% of patients) or platelets (19%), 54% had febrile neutropenia, 31% grade 3/4 asthenia, and
26% abandoned the study due to toxicity. Three toxic deaths occurred. In 57 non-GIST patients objective activity was 45.6% (95%
CI, 32 to 58%). Conclusion. At least 4 cycles were tolerated by 71% of patients, most receiving DXR 50 mg/m2 plus IFOS 10–12
g/m2, with substantial toxicity.
Copyright © 2006 A. L´ opez-Pousa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Doxorubicin (DXR) and ifosfamide (IFOS) are two active
agents against advanced soft tissue sarcomas (ASTS), which
havebeencombinedinanattempttoimprovetherapeuticef-
ﬁcacy [1]. However, the combination of DXR 50mg/m2 plus
IFOS 5g/m2 was not more active than single agent DXR at
75mg/m2 in an EORTC study [2], although other authors
havereportedahigherresponseratewhen7.5g/m2 IFOSwas
added to DXR [3] or to a combination of DXR and dacar-
bazine[4].TheobjectiveactivitydetectedforthoseIFOSplus
DXRcombinationsrangedfrom25%to34%.Theconcourse
of hematopoietic growth factors allowed the administration
offullDXRdoses,butacomparativestudyofIFOSat5g/m2,
combined with 50 or 75mg/m2 DXR, was negative with re-
spect to eﬃcacy and overall survival, with progression-free
survival being signiﬁcantly longer in the high-dose arm [5].
Second-line studies conducted at higher IFOS doses dis-
closedadose-response relationshipforthisagent[6,7],what
originated a series of single-arm Phase II trials combining
an anthracycline with high-dose IFOS (≥ 10g/m2). At the
MD Anderson Hospital Cancer Center, two consecutive tri-
als explored DXR doses of 75 or 90mg/m2 added to 10g/m2
IFOS. All patients included had at least one episode of febrile
neutropenia, and thrombocytopenia was signiﬁcant in both
pilot trials, so that 50% of patients had toxicity grade 4 on2 Sarcoma
platelets [8]. When IFOS 12.5g/m2 was combined with DXR
at 60mg/m2, grade 4 thrombocytopenia occurred in 13% of
patients, and 74% received 4 to 6 cycles at full doses [9]. In
another study, the combination of 12.5g/m2 IFOS with 4-
epidoxorubicin (EPI) at 90mg/m2 induced grade 4 throm-
bocytopenia in 35% of patients [10], while EPI at 110mg/m2
plusIFOS10g/m2 werethedosesrecommendedafteraPhase
It r i a l[ 11]. In those trials, grade 4 neutropenia occurred in
70–100% of patients, a toxicity that was not considered lim-
iting. Objective activity of those regimens, usually delivered
every 3 weeks, varied from 52% to 69%, although random-
ized studies comparing their eﬃcacy with that of single agent
DXR or standard-dose combinations are still lacking.
When this study was planned it appeared that, in those
high-dose regimens, the dose of one of the agents should
be compromised in order to cause a toxicity that would al-
low the administration of at least 4 to 6 cycles. Furthermore,
our group had recently concluded a ﬁrst-line trial with IFOS
given at 14g/m2 every 4 weeks [12]. With those antecedents,
we decided to conduct a study to determine the dose of IFOS
that would cause an acceptable toxicity when combined with
50mg/m2 DXR. The initial dose of 12g/m2 IFOS was ad-
justed in subsequent cycles in function of the hematologic
toxicity encountered in each patient. Our purpose was also
to evaluate the activity of the combination.
MATERIALS AND METHODS
Selectioncriteria
Thecriteriaforinclusioninthetrialwereahistologicdiagno-
sis of soft tissue sarcoma (malignant mesothelioma and ex-
traosseous chondrosarcoma, osteosarcoma or Ewing/PNET
were excluded), locally advanced or metastatic disease, age
between 15 and 65 years, no prior chemotherapy either
adjuvant or for advanced disease, bidimensionally measur-
able disease progressing in the last 4 weeks, performance
status (WHO) ≤ 2, leukocytes > 4.000/mm3, platelets
> 100.000/mm3, serum creatinine < 1.5mg/dL, creatinine
clearance > 60mL/min, total bilirubin > 1.5mg/dL, and al-
bumin> 30g/L.Patientshadtohavealeftventricleejectional
fraction (LVEF) at baseline > 50%. Patients were excluded if
they had a severe associated disease, CNS metastases, a sec-
ondprimarytumor(exceptforadequatelytreatedinsitucer-
vical carcinoma and squamous or carcinoma of the skin), if
they had received radiation therapy on the only measurable
lesion, or if diﬃculties infollow-upwereexpected. Thestudy
protocolwasapprovedbytheEthicalCommitteeofeachpar-
ticipating institution and an informed written consent was
obtained from all patients.
Treatment
All patients received doxorubicin at a ﬁxed dose of 50mg/m2
infused IV over 10–20 minutes on day 1 immediately fol-
lowed by a continuous infusion of ifosfamide (IFOS) with
GM-CSFsupport,every4weeks.TheinitialdoseofIFOSwas
12g/m2 (plus 50% Mesna) (Pras-Pharma, Madrid, Spain)
and was given according to the following schedule: on day
1 500mL of normal saline (NS) were administered IV in
1h o u r ,f o l l o w e db yI F O S2 g / m 2 plus Mesna 1g/m2 in
1.000mL NS in 2 hours, and the rest of the dose was in-
fused at a rate of 2g/m2 IFOS every 24 hours. Daily dose
was diluted in 1.000mL NS. At the end of IFOS infusion
3 additional doses of Mesna 600mg/m2 every 6 hours were
given, either orally or IV, with an oral intake of 1.500mL or
1.500mL NS IV in 12 hours. All patients received sodium bi-
carbonate 1/6M 250mL/day (40mEq/day) with IFOS infu-
sion. No extra ﬂuid intake was required during therapy, and
patients were instructed to void frequently. If they noted dy-
suria, an additional dose of Mesna 1g IV bolus was admin-
istered and the amount of Mesna in the rest of the infusion
was increased to a 100% that of IFOS. Prophylactic GM-CSF
(molgramostin, Schering-Plough SA, Barcelona, Spain) was
started on day 7 and given subcutaneously at 5µg/Kg/day for
10consecutivedays,oruntilleukocytecount ≥ 10.000/mm3.
Values of hemoglobin were kept above 10g/100mL transfus-
ing red-packed cells when necessary.
Weekly BCC were performed, and cycles were repeated
if leukocytes were ≥ 3.000/mm3, granulocytes were ≥
1.500/mm3, and platelets were ≥ 100.000/mm3 on day 28.
Otherwise, cycles were delayed until reaching those ﬁgures,
and the patient interrupted therapy if no recovery was de-
tected after 3 weeks. There were four dose levels of IFOS
in this study (10, 12, 13, and 14g/m2), while the dose of
doxorubicin was kept constant at 50mg/m2.I F O Sd o s ew a s
adapted to the toxicity observed in the prior cycle with
the duration of the infusion modiﬁed to maintain the rate
of 2g/m2/24h. The dose was progressively increased to 13
and 14g/m2 if at nadir leukocytes were ≥ 1.000/mm3 and
platelets were ≥ 75.000/mm3 in the absence of fever. The
dose was reduced one level when neutropenic fever was ob-
served, if platelets were < 50.000/mm3 for more than 1
week, if platelets were < 25.000/mm3, or if stomatitis grade
3 to 4 was reported. If any of those situations recurred
at 10g/m2, the patient was to abandon the trial. The pa-
tient was also withdrawn from the study if creatinine clear-
ance was < 60mL/L or serum creatinine was > 2.5t i m e s
t h a nn o r m a lu p p e rv a l u e ,i fad e c r e a s ei nL V E F> 15%
with respect to baseline was detected, or after any toxic-
ity that might endanger the life of the patient. In the pres-
ence of transient hallucinations the patient continued on
study, but no if important somnolence, confusion, toxic psy-
chosis or coma (grade 3 to 4 neurocortical toxicity) oc-
curred.
Antiemesis consisted of dexamethasone 8mg IV bolus
plus either granisetron 3mg or ondansetron 8mg IV on
day 1, according to each center’s routine, followed by oral
granisetron 1mg or ondansetron 4mg every 12 hours for 6
consecutive days. The use of psychotropic drugs such as ben-
zodiazepines and narcotic analgesics was discouraged during
the infusion of IFOS, as well as the use of aminoglycosides to
treat febrile episodes.
Baseline studies included a clinical history and physi-
cal examination, evaluation of the performance status, as-
sessment of the diﬀerent tumoral lesions and measurementA. L´ opez-Pousa et al 3
of all evaluable lesions (physical examination, thorax X-ray,
computed tomographic scan, but not ultrasound, were valid
procedures), thorax X-ray, ECG, LVEF, complete and diﬀer-
ential cell blood count (CBC), serum chemistries with glu-
cose, sodium, potassium, calcium, magnesium, phosphorus,
bicarbonate, BUN, creatinine, total protein, albumin, AST,
ALT, alkaline phosphatase, LDH, total bilirubin, urine exam-
inationbymicroscopyanddipstick,andcreatinineclearance.
A complete CBC was performed at the end of IFOS infusion
and weekly thereafter, while physical examination, evalua-
tion of the performance status, CBC, blood chemistries and
microscopic examination of the urine were repeated before
each new cycle. A thorax X-ray and the measurement of all
evaluable lesions were repeated every 8 weeks, and LVEF was
determined every 4 cycles.
WHO criteria were followed to evaluate response to ther-
apy[13].Anyobjectiveremissionhadtobeconﬁrmedatleast
4 weeks later and was externally reviewed. Complete remis-
sion (CR) was the complete disappearance of all signs and
symptoms of disease for at least four weeks, and a pathologic
complete response (pCR) was the absence of viable tumor
in the surgical specimen of the evaluated lesion. Partial re-
mission (PR) was considered a decrease of at least 50% in
the sum of the products of the two longest perpendicular
diameters of every measurable lesion, in the absence of any
progressive lesion, and stable disease (SD) was any change
that did not qualify for either a partial response or progres-
sive disease. The appearance of a new lesion or an increase
of at least 25% in any measurable lesion was termed progres-
sive disease (PD), while rapid progression was the appear-
ance of a new lesion or an increase in any measurable lesion
higher than 50% after only one cycle of therapy. In the ab-
sence of rapid progression, at least 2 cycles were necessary to
evaluate antitumor activity. Therapy continued in the pres-
ence of a PR or SD and the maximum number of cycles per
protocol was 6, although rescue surgery or other potentially
curative procedures could be attempted at the discretion of
each investigator only after 4 cycles of therapy for reasons of
uniformity. Patients could continue on protocol after 6 cy-
cles at investigator discretion. All patients receiving at least
1 cycle were considered evaluable for toxicity, and those cy-
cles with weekly CBC were assessable for hematologic toxic-
ity. Toxicity was graded according to Common Toxicity Cri-
teria of the National Cancer Institute (NCI) (Version 1.0).
Dose-intensity per patient was calculated by dividing total
dose administered per square meter by the total duration of
treatment in weeks plus 4 additional weeks.
The duration of objective remissions was measured from
the date ﬁrst observed until the date of progression, and time
to progression was measured from the date of inclusion until
progressive disease was ﬁrst observed. In both analysis pa-
tients were censored on the date any other therapeutic pro-
cedure (ie, rescue surgery) was performed. Overall survival
was measured from the date of patient inclusion until death
from any cause or last control. Actuarial time to progression
and overall survival were determined by the method of Ka-
plan and Meier. Student-t test was applied to compare mean
values. All p-values are two-tailed.
Table 1: Patient characteristics.
Included 73
Eligible 71
Male/female 29/42
Median age (range) 55 (22–65)
Performance status:
02 4
13 4
21 3
Histology:
Leiomyosarcoma 16
GIST 8
Fibrosarcoma 6
Liposarcoma 6
Malignant ﬁbrous histiocytoma 5
Angiosarcoma 4
Neurosarcoma 4
Synovial cell sarcoma 3
Rhabdomyosarcoma 2
Mixed mesodermal sarcoma 2
Other 22
Grade of malignancy:
11 4
22 2
33 5
Sites of disease:
Primary/local recurrence 41
Lung 29
Liver 10
Other 13
To determine the minimum size of the sample necessary
to detect at least a 20% of activity, we followed the two-stage
Phase II design of Gehan [14]. Once this activity was con-
ﬁrmed in the ﬁrst 25 patients, it was decided to continue the
study to further characterize the toxicity of the schedule in a
multicenter setting.
RESULTS
Patientcharacteristics
From July 1997 to July 1999, 73 patients were included in the
study. Two were considered ineligible (one with a low per-
formance status and another exposed to prior chemother-
apy). One patient was not evaluable for any analysis due to
lack of data, 70 were assessable for toxicity and 64 for an-
titumor activity. Six patients were not valid for analysis of
eﬃcacy: 5 received only 1 cycle and one patient had a toxic
death after the second cycle. Main characteristics of eligible
patients are presented in Table 1. Retrospectively, a diagnosis
of gastrointestinal stromal sarcoma tumor (GIST) was done4 Sarcoma
Table 2: Number of patients and dose of ifosfamide during the ﬁrst
6 cycles of treatment.
Dose of ifosfamide
10g/m2 12g/m2 13g/m2 14g/m2 Total
Cycle number (patients)
1 5(a) (0.07) 65 (0.93) — — 70
2 19 (0.30) 23 (0.36) 22 (0.34) — 64
3 18 (0.37) 17 (0.35) 4 (0.08) 10 (0.20) 49
4 15 (0.40) 10 (0.27) 4 (0.11) 8 (0.22) 37
5 9 (0.37) 6 (0.25) 3 (0.13) 6 (0.25) 24
6 8 (0.40) 6 (0.30) 2 (0.10) 4 (0.20) 20
(a)Number of patients (%).
in 8 patients. In 20 patients the primary tumor was the only
site of disease and the lungs in 16. Sixteen patients had re-
ceived radiotherapy before.
Treatment
In total 277 cycles were delivered, with a median of 3 per pa-
tient (range 1–10). Six patients received only 1 cycle of ther-
apy due to hematologic [1] or cardiac toxicity [1], treatment
refusal[1],rapidprogression[1]oratoxicdeath[2].Accord-
ing to ifosfamide dose, 81 cycles were given at 10g/m2, 130
at 12g/m2,3 3a t1 3g / m 2, and 34 at 14g/m2.I nTable 2 we
summarized the number of cycles given by ifosfamide dose
level during the 6 cycles projected by protocol. Roughly, one
third of cycles were given at 10, at 12, and at > 12g/m2 IFOS
during cycles 2 to 6. Five patients erroneously started ther-
apy at 50mg/m2 doxorubicin and 10g/m2 ifosfamide: 1 re-
fused further therapy, 2 had excessive toxicity for increasing
dose, 1 continued at 10g/m2 and 1 had the dose of ifos-
famide increased to 12g/m2 in subsequent cycles. Among
the 65 patients who received the ﬁrst cycle at 12g/m2 ifos-
famide, 22 had the dose increased to 13g/m2 and 16 re-
duced to 10g/m2 in the second cycle. The reasons to aban-
don the study during the ﬁrst 6 cycles of therapy are sum-
marized in Table 3. Ten out of 21 patients (48%) leaving
the trial for toxicity were receiving IFOS at 10g/m2 and 7
(33%) at 12g/m2. Twenty patients completed 6 cycles, and
6 of them continued on therapy afterwards. Fifteen per-
cent of the ﬁrst 6 cycles were delayed, either due to toxicity
(50%), patient request, or bed availability, median cycle in-
terval being 28 days (range 26–35 days) with only 5% of cy-
c l e sg i v e no nd a y3 5 .M e a nd o s er e c e i v e d( ± standard devia-
tion)inthosecycleswas50±1.58mg/m2 fordoxorubicinand
11.70±1.43g/m2 forifosfamide,andmeandoseintensitywas
11.98±0.70mg/m2/weekforDXRand2.82±0.34g/m2/week
for IFOS.
Hematologictoxicity
Sixty-nine patients and 254 cycles were assessable for hema-
tologic toxicity. In Table 4 we present the maximum grade of
Table 3: Reasons to abandon the study during the ﬁrst 6 cycles of
treatment.
Toxicity(a) Progression Additional End of
Total therapy(b) therapy
Cycle number
1 5(c) 1— — 6
2 87— — 15
3 561 — 12
4 225 4 13
5 121 — 4
6 —— 86 14
(a)Toxicity includes excessive toxicity, patient refusals, and toxic
deaths.
(b)Surgery, radiotherapy or both.
(c)Number of patients.
this toxicity per patient during the whole treatment period.
Agrade3to4decreaseinhemoglobinvalueswasobservedin
40% of patients (16% of cycles), and in platelet count in 43%
of patients (19% of cycles), while 82% and 79% had grade 3
to 4 toxicity on leukocytes or granulocytes in 58% and 58%
of cycles, respectively. The percentage of patients with grades
3 and 4 hematologic toxicity by dose of ifosfamide during
the ﬁrst 6 cycles of therapy is presented in Table 5. In those
ﬁrst 6 cycles, mean platelet values decreased with the num-
ber of cycles delivered (P<. 0001). In patients with gran-
ulocytes < 1.000/mm3 (grade 3 to 4), the nadir occurred
on day 12 (range 5–30), with mean granulocyte values of
0.22/mm3 (range 0–0.97). In 83% of cycles, recovery to min-
imum hematologic values required for therapy was already
reached by day 21.
Nonhematologictoxicity
T h em o s tf r e q u e n tg r a d e3t o4s i d e - e ﬀects were infection
(46% of patients), vomiting (27%), asthenia (31%), anorexia
(28%), and stomatitis (10%) (see Table 6). All episodes of
neurocortical toxicity grade 3 consisted of visual hallucina-
tions, while grade 1 to 2 episodes were usually character-
ized by a mild-to-moderate somnolence. Two patients re-
ferred asterixis with limitation to hold objects, and another
two noted peripheral paresthesias. Serial LVEF determina-
tions were available from 52 patients, and in 17 a mean de-
crease of 10.94 ± 4.14% was noted after therapy, with only
5 presenting values below 50% (range 41–47%). All 3 pa-
tients with serial measurements performed within the ﬁrst
cycle had a transient decrease in LVEF of 17%, 20%, and 7%,
respectively, with one of them associated with symptomatic
left cardiac failure that led to treatment interruption. An-
other patient who had received a cumulative DXR dose of
250mg/m2 developed clinical cardiac failure 1 year after the
end of protocol therapy, when an LVEF was 30%. Increased
serumcreatininevaluesobservedin9patientswerereversible
in 6, 2 with grade 1 toxicity were not further evaluated, and
one patient abandoned the study due to persistent creatinine
clearance values < 60mL/min concomitantly with a grade 1A. L´ opez-Pousa et al 5
Table 4: Maximum hematologic toxicity (% of patients).
Grade CTC
0123 4
Hemoglobin 165 3 3 19
Leukocytes 8—1 0 2 2 6 0
Granulocytes 12 3 6 12 67
Platelets 15 29 13 24 19
increase in serum creatinine. No episodes of acute renal fail-
u r ew e r eo b s e r v e d .
During the study 38 patients (20% of cycles) had at
least one episode of febrile neutropenia, requiring 50 hos-
pital admissions for support. Although out-patient treat-
ment through a central catheter was allowed, all patients but
one received treatment as inpatients. If days of hospitaliza-
tion due to both treatment and support measures are added,
75.4% of cycles required less than 7 days at hospital (median
5, range 3–6 days) and 24.6% more than 7 days (median 13,
range 8–27 days). Red-packed cell transfusions were given to
41 patients in 29% of cycles, and 11 received platelet transfu-
sions in 11 cycles. Sixteen patients in 23 cycles referred tox-
icity to GM-CSF that usually consisted of an itchy erythema
plus mild swelling at the site of puncture (13 patients); 3 pa-
tients noted night sweats, fever, or a poor tolerance to GM-
CSF administration. Two patients were shifted to G-CSF. All
three episodes of toxic death were secondary to neutrope-
niaplusunrecoverablesepsisinonepatientcoincidentalwith
neurocortical and renal toxicity.
Responsetotherapyandevolution
In 64 patients assessable for activity, the best response ob-
served was a complete remission in 1 patient, a partial re-
mission in 26, stable disease in 24, and progressive disease
in 13, for an overall activity rate of 42% (95% CI, 30–54%).
In 8 GIST patients, 1 partial remission, 2 stabilizations and 4
progressions were noted, with 1 being nonevaluable. If GIST
patients are excluded, response rate was 45.6% (95% CI, 32–
58%). Sensitive histotypes were leiomyosarcoma (8/14), an-
giosarcoma (2/4), neurogenic sarcoma (2/4), rhabdomyosar-
coma (1/2), mixed mesodermal sarcoma (1/2), ﬁbrosarcoma
(2/6),synovialcellsarcoma(1/3),malignantﬁbroushistiocy-
toma (1/4) or liposarcoma (1/5) among others. Activity was
notedontheprimarytumor(44%),lung(48%),liver(33%),
or other lesions (15%). Mean time (± SD) to achieve an ob-
jectiveremissionwas2.8±1.5months(range1.5–8months).
No correlation was observed between the mean dose of IFOS
received and response. Mean duration of response was 7.87
months (95% CI, 5.88–9.85 months), and mean time to pro-
gression was 9 months (95% CI, 7–11 months).
The reason to abandon the study was excessive toxicity in
16 patients, treatment refusal in 2 (after 1 and 5 cycles, resp),
salvage surgery in 6, disease progression in 19, and treatment
completion in 24. Four patients ﬁnished protocol therapy af-
ter 4 cycles in the absence of toxicity or progression. Toxicity
Table 5: Grades 3 and 4 hematologic toxicity by ifosfamide dose
during the ﬁrst 6 cycles (% of patients).
Dose of ifosfamide
10g/m2 12g/m2 13g/m2 14g/m2
Hemoglobin 21/7 20/3 9/4.5 36/9
Leukocytes 18/57 19/42 41/23 27/45
Granulocytes 0/71 19/46 9/45 9/63
Platelets 46/11 14/9 9/9 0/36
that led to treatment interruption consisted of hematologic
depression associated to febrile neutropenia [11], poor gen-
eral tolerance to therapy [4], or a persistent decrease in crea-
tinine clearance (< 60mL/min) in 1 patient. The occurrence
of excessive toxicity was not related with sex, performance
status, or site of disease, but those patients with severe tox-
icity tended to be older (mean ± SD, 54 ± 10 years versus
49 ± 9.7y e a r s ,P = .057). In all, 16 patients were submitted
torescuesurgery(9inpartialremissionand7withstabledis-
ease) and 11 apparently achieved a complete remission. Five
ofthosepatientsalsoreceivedadjuvantradiotherapy,andan-
other 3 patients received radiotherapy upon completion of
protocol therapy.
At the time of last analysis, 60 patients (86%) had died
of disease, 3 had a toxic death, 2 were lost to follow-up (one
of them without evidence of disease 6 years after completing
therapy), and 5 patients were alive, 2 with active disease and
3 with no evidence of disease (two rescued with surgery and
one with a durable complete remission after temozolomide).
Median (± ds) overall survival for the whole series was 17±2
months (95% CI, 13–22 months). No relation between sur-
vival and grade of hematologic toxicity was observed.
DISCUSSION
In this study, ASTS patients were treated with IFOS at an
initial dose of 12g/m2 combined with DXR 50mg/m2 every
4 weeks, with the dose of IFOS adjusted in the 10–14g/m2
range according to the hematologic nadir. The dose of IFOS
was increased in 34% of patients, and 30% had the dose
reduced to 10g/m2 in the second cycle. These proportions
were maintained all along the study, so that approximately
one third of patients each received 10, 12, and > 12g/m2
IFOS (plus 50mg/m2 DXR) during the ﬁrst 6 cycles, point-
ing perhaps to interpatient diﬀerences in drug metabolism
(Tables 2 and 5). A criticism to this trial may be the low
dose of DXR administered, which led to a low dose inten-
sity (12.5mg/m2/week) compared with the 25mg/m2/week
of DXR given as a single agent at standard doses. As 83% of
cycles had hematologic values suitable for repeating therapy
on day 21, one can speculate whether this schedule would
had been tolerated every 3 weeks. However, 26% of patients
were taken oﬀ study due to excessive toxicity and three toxic
deathsoccurred,indicatingthatthereislittlemarginfordose
increase.
The three studies that explored a combination of IFOS
12g/m2 plus DXR 60mg/m2 repeated every 3 weeks in a6 Sarcoma
Table 6: Nonhematologic toxicity (% of patients).
Grade
0123 4
Nausea 10.1 20.3 48 20.3 1.4
Vomiting 18.6 17.1 37.1 24.3 2.9
Diarrhea 81.2 11.6 5.8 1.4 —
Stomatitis 54.3 16 20 8.6 1.4
Asthenia 7.4 17.6 44.1 25 6
Anorexia 13.2 25 34 23.5 4.4
Cardiotoxicity 81.2 11.6 3 4.3 —
Neurocortical 55 24.6 7.2 13 —
Cutaneous 88 6 6 — —
Alergia 93 6 1 — —
Fever 38.6 7 38.6 7.1 8.6
Infection 45 3 6 36 10
Creatinine 86 11 3 — —
Hematuria 48 40 8 4 —
small number of ASTS patients encountered excessive tox-
icity. In the ﬁrst, only 85% of the planned dose for both
agents was given [9]. The second was a Phase I trial testing
two IFOS dose levels (10 and 12g/m2)a d d e dt oD X R( 5 0 –
90mg/m2). DXR 60mg/m2 plus 12g/m2 IFOS was the maxi-
mum tolerated dose due to the presence of neutropenia last-
ing more than 4 days and thrombocytopenia grade 4 in 3 out
of 4 patients. However, when 10g/m2 IFOS were combined
with 60–90mg/m2 DXR, the dose limiting toxicity was not
reached [15]. In the third study, 8 out of 14 (57%) patients
with metastatic disease treated at DXR 60mg/m2 plus IFOS
12g/m2 every 3 weeks discontinued therapy due to toxicity
[16].
In this trial the dose of IFOS was adjusted in each pa-
tient in function of the toxicity. The dose limiting toxicity
was febrile neutropenia, which aﬀected 54% of patients, a
ﬁgure equal to that observed in our Phase II trial with high-
dose IFOS conducted in a similar patient population [12]. In
spite of the prophylactic use of hematopoietic growth fac-
tors, grade 4 granulocytopenia occurs in 70–100% of pa-
tients treatedwithhigh-dose regimens, andfebrileneutrope-
nia is reported in 35–100% of patients exposed to DXR plus
high-dose IFOS [8, 9, 15] or in 13–54% of those treated with
combinations of EPI plus IFOS at 9–12g/m2 [10, 17, 18], al-
though septic deaths are seldom reported. This grade of tox-
icity must be accepted as inherent to any high-dose regimen
applied to patients with ASTS. Grade 4 thrombocytopenia
was detected in 19% of our patients. It was cumulative in na-
ture, but did not lead to delays or interruptions of therapy.
This incidence of grade 4 thrombocytopenia seems accept-
able when compared with the 50% observed in trials which
incorporated DXR at 75–90mg/m2 to 10g/m2 IFOS [8], or
the 40–75% of the combination of DXR 60mg/m2 plus IFOS
12g/m2 [15, 16], what eventually limits the number of cy-
cles that can be given at full doses. Other toxic eﬀects noted
are well known and were similar to those observed by oth-
ers. In any case, these high-dose schedules are too toxic for
routine use and should only be administered in experienced
centers.
Due to the toxicity observed in this trial and in order to
administer higher doses of DXR, we explored a sequential
approach in a subsequent study, administering dose-dense
DXR (3 cycles at 90mg/m2 repeated every 2 weeks) followed
by high-dose ifosfamide (3 cycles at 12.5g/m2 every 3 weeks)
[19]. In this trial, which included 57 patients, 7% of patients
withdrew due to refusal or excessive toxicity, 24% had febrile
neutropenia, 24% had thrombocytopenia grade 3 to 4, and
66% completed the 6 projected cycles of therapy. This reg-
imen oﬀered a better toxicity proﬁle and compliance when
compared with either the single agent IFOS or the presently
reported study, with a similar antitumor activity (remission
rate 38%; 95% CI, 25–51%), and it may provide a thera-
peutic option for ASTS patients. For this reason, it was se-
lected for comparison with single agent DXR (75mg/m2 ev-
ery3weeks)inaPhaseIIIstudy,presentlyundercourse.Pro-
longation of IFOS infusion oﬀers another alternative, more
cumbersome, to reduce the toxicity of DXR plus high-dose
IFOS combinations. The study of the Italian Sarcoma Group
showed that IFOS 13g/m2 infused over 12 days and bolus
DXRat75mg/m2 onday8couldbecombinedevery4weeks,
with grade 4 neutropenia and thrombocytopenia observed,
r e s p e c t i v e l y ,i n6 6 %a n d8 %o fp a t i e n t s[ 20].
Antitumor activity in ASTS (excluding GIST patients)
was45.6%,whichisbelowthe54–69%ofﬁguresreportedfor
other high-dose regimens tested [8, 10, 15, 17, 18, 20], with
the exception of the 25% reported in 12 metastatic patients
[16]. Perhaps the low DXR dose administered inﬂuenced our
results,althoughthisﬁgurecoincideswiththatofotherstud-
ies from our Group [12, 19], and no deﬁnitive conclusions
can be drawn from small trials conducted in such a heteroge-
neous group of tumors. However, the results of most studies
areconsistent,andsuggestthathigh-doseregimensmayhave
ah i g h e re ﬃcacy than standard-dose schedules, an impres-
sionthatshouldbetestedinadequatelysizedrandomizedtri-
als.Salvagesurgerywaspossiblein25%ofevaluablepatients,
and 56% of them had obtained a partial remission during
protocol therapy. Rescue surgery is performed in about 30%
of ASTS patients included in high-dose studies [10, 17, 18],
being diﬃcult to deduce to what extent chemotherapy has
facilitated surgery. For this reason, resectability of lesions
should be established beforehand through clear deﬁnitions
included among the selection criteria. This aspect, addressed
in a recent paper [21], could be considered a stratiﬁcation
criterion in future studies.
From the therapeutic results obtained in some solid tu-
mors, it has been proposed that hematologic toxicity is a bet-
ter parameter than dose intensity to measure dose adequacy,
and that outcome is related to the grade of that toxicity [22].
According to this, the doses of any chemotherapeutic regi-
men should be adjusted to cause at least moderate hemato-
logic toxicity to every patient to compensate for diﬀerences
in tolerance [23]. In ASTS patients, it is diﬃcult to test that
proposal due to the very heterogeneous nature of the tumors
grouped under the term sarcoma. With this contention, if
toxicity is related to outcome, then the regimen we testedA. L´ opez-Pousa et al 7
would have reached a limit, as well as other high-dose reg-
imens combining IFOS and an anthracycline, that will un-
likely be improved by pushing further the doses delivered.
New agents would be necessary to improve the poor thera-
peutic results obtained in ASTS patients, and the diﬀerences
in biology and in sensitivity between the diﬀerent sarcoma
subtypes should be exploited.
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